 GSK is on course to have its new RSV vaccine fast-tracked in Europe after the EMA validated its marketing application based in impressive results from a recent phase III trial. That study showed 83 efficacy against respiratory syncytial virus-lower respiratory tract disease in adults aged 60 years and above with a favourable safety profile read more. 